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Yoshinobu Onuma, MD, PHD,* Patrick W. Serruys, MD, PHD{{ABSTRACTOBJECTIVES This study sought to evaluate the mechanism of post-procedural cardiac biomarker (CB) rise following
device implantation.
BACKGROUND A fully bioresorbable Absorb scaffold, compared with everolimus-eluting metallic stents (EES),
might be associated with a higher incidence of periprocedural myocardial injury.
METHODS In 501 patients with stable or unstable angina randomized to either Absorb (335 patients) or EES (n ¼ 166) in
the ABSORB II trial, 3 types of CB (creatine kinase, creatine kinase-myocardial band, and troponin) were obtained before
and after procedure. Per protocol, periprocedural myocardial infarction (PMI) was deﬁned as creatine kinase rise >2 the
upper limit of normal with creatine kinase-myocardial band rise.
RESULTS Incidence of side branch occlusion and any anatomic complications assessed by angiography was
similar between the 2 treatment arms (side branch occlusion: Absorb: 5.3% vs. Xience: 7.6%, p ¼ 0.07; any
anatomic complication: Absorb: 16.4% vs. EES: 19.9%, p ¼ 0.39). Fourteen patients who presented with
recent myocardial infarction at entry with normalized creatine kinase-myocardial band according to the protocol
were excluded for post-CB analysis. The overall compliance for CB was 97.8%. The CB rise subcategorized in
7 different ranges was comparable between the 2 treatment arms. PMI rate was numerically higher in the
Absorb arm according to the per-protocol deﬁnitions, and treatment with overlapping devices was the only
independent determinant of per-protocol PMI (odds ratio: 5.07, 95% conﬁdence interval: 1.78 to 14.41,
p ¼ 0.002).
CONCLUSIONS There were no differences in the incidence of CB rise and PMI between Absorb and EES. Device overlap
might be a precipitating factor of myocardial injury. (ABSORB II Randomized Clinical Trial: A Clinical Evaluation to
Compare the Safety, Efﬁcacy, and Performance of Absorb Everolimus Eluting Bioresorbable Vascular Scaffold System
Against Xience Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease
Caused by De Novo Native Coronary Artery Lesions [ABSORB II]; NCT01425281). (J Am Coll Cardiol Intv 2015;8:1053–63)
© 2015 by the American College of Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
CB = cardiac biomarker
CI = conﬁdence interval
CK = creatine kinase
CK-MB = creatine kinase-
myocardial band
EES = everolimus-eluting
stent(s)
IVUS = intravascular
ultrasound
OR = odds ratio
PMI = periprocedural
myocardial infarction
RVD = reference vessel
diameter
SBO = side branch occlusion
TIMI = Thrombolysis In
Myocardial Infarction
ULN = upper limit of the
normal
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1054T he bioresorbable everolimus-elutingscaffold (Absorb, Abbott Vascular,Santa Clara, California) was devel-
oped to provide a novel approach to treat cor-
onary artery stenosis with transient vessel
support and drug delivery (1–4). The perfor-
mance of the second-generation Absorb was
investigated in the ABSORB Cohort B trial
(ABSORB Clinical Investigation, Cohort B),
which reported excellent clinical results
(5–7). However, the clinical relevance of
this technology in comparison with metallic
drug-eluting stents still remains a matter of
debate due to the absence of randomized
comparative data between the Absorb and
conventional metallic drug-eluting stents.
The ABSORB II (ABSORB II Randomized
Clinical Trial: A Clinical Evaluation to Com-
pare the Safety, Efﬁcacy, and Performance
of Absorb Everolimus Eluting Bioresorbable
Vascular Scaffold System Against XienceEverolimus Eluting Coronary Stent System in the
Treatment of Subjects With Ischemic Heart Disease
Caused by De Novo Native Coronary Artery Lesions)
(8) is the ﬁrst randomized clinical trial assessing the
clinical outcomes in 501 patients treated with either
the Absorb or the metallic everolimus-eluting stent
(EES) (Xience, Abbott Vascular).
In a nonrandomized comparison using historical
data, the Absorb scaffold was associated with a
higher incidence of post-procedural side branch oc-
clusion (SBO) than EES was (9). Given the increased
strut thickness of Absorb, a potential concern
exists that it might be associated with a higher in-
cidence of periprocedural myocardial injury and
periprocedural myocardial infarction (PMI) than
newer-generations of DES are (9). Therefore, the aim
of this study is to investigate the incidence and
mechanism of post-procedural cardiac biomarker
(CB) rise following Absorb scaffold versus metallic
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STUDY DESIGN. The ABSORB II randomized con-
trolled trial design has been described in detail
previously (8). In brief, the ABSORB II trial was pro-
spective, multicenter, single-blinded, randomized
controlled trial that compared the safety and efﬁcacy
of the Absorb versus the EES in patients with stable
or unstable angina due to up to 2 de novo coronary
artery lesions, each located in different major
epicardial vessels, all with an angiographic maximal
luminal diameter between 2.25 and 3.8 mm as esti-
mated by online quantitative coronary angiography
and a lesion length of #48 mm. The detail of both
study devices is provided in the Online Appendix
(2,10,11). A total of 501 patients were randomized
2:1 into either the Absorb arm or the EES arm in
Europe and New Zealand.
QUALITATIVE AND QUANTITATIVE ANGIOGRAPHIC
ASSESSMENT. SBO, occurrence of no-reﬂow, abrupt
closure, dissection, and distal embolization in main
and side branches were assessed qualitatively at pre-
procedure, after balloon pre-dilation, after device
deployment, and after ﬁnal balloon inﬂation. Coro-
nary dissections were assessed using the National
Heart, Lung and Blood Institute criteria (12,13). In the
present study, according to the underlying “anatomic
complications” (assessed by angiography), CB rise
and PMI were classiﬁed into 3 types: type 1—CB rise
and PMI due to SBO; type 2—CB rise and PMI due to
other anatomic complications (e.g., slow ﬂow or no-
reﬂow, distal embolization, thrombus during proce-
dure, ﬂow-limiting dissection, coronary dissection of
National Heart, Lung and Blood Institute type D or E,
or disruption of collateral ﬂow); type 3—CB rise and
PMI without angiographically identiﬁable causes for
the CB rise (Figure 1).
The quantitative angiographic analysis by the
2-dimensional single-vessel quantitative coronary
angiography (CAAS 5.10, Pie Medical BV, Maastricht,the Netherlands; yDepartment of Cardiology, Fujita
dical Center, Amsterdam, the Netherlands; xMedical
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FIGURE 1 Classiﬁcation According to Angiographic Mechanism After Revascularization
Type 1: cardiac biomarker rise due to side branch occlusion. Type 2: cardiac biomarker rise due to other anatomic complications. Type 3: cardiac biomarker rise without
any identiﬁable anatomic causes in the coronary artery. Pre-procedure angiography showed a focal stenosis (white arrows), side branches in the target lesion
(yellow arrows), and distal embolization was observed after device implantation (red arrow).
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1055the Netherlands) included the reference size of the
side branch and the percentage of diameter stenosis
of any side branch lesion as well as the side branch
TIMI (Thrombolysis In Myocardial Infarction) ﬂow
grade at the following time points: pre-procedure;
after pre-dilation; after post-dilation; and post-
procedure (9). The region of interest was deﬁned as
the study device implantation site and the 5-mm
proximal and distal margins in the main branch
(Figure 2). A detailed side branch analysis was per-
formed of all side branches identiﬁed within the
region of interest pre-procedurally, during the course
of the intervention to capture any transient compli-
cations, and post-procedure. SBO was deﬁned as a
reduction in the TIMI ﬂow grade 0 to 1. Accordingly,
side branches with pre-procedural TIMI ﬂow grade0 or 1 were excluded. Transient or ﬁnal SBO was
deﬁned as SBO that occurred during the procedure
and either disappeared or persisted at the end of
the procedure. Angiographic assessment of the side
branch was based on the consensus of 3 experienced
cardiologists (Y.I., T.M., and Y.C.) and assessed in
at least 2 different projections, with angiographic
assessment for each side branch.
IVUS IMAGE ACQUISITION. Intravascular ultrasound
(IVUS) was mandatory before and after the procedure.
The detail of an image acquisition is described in
Online Figure 1.
BLOOD SAMPLING. The protocol mandated that
blood sampling for cardiac enzymes was to be col-
lected within 6 h before the index percutaneous
FIGURE 2 Detailed Analysis of SBO
The QCA analysis delineates 5-mm proximal (A) (red double arrow) and distal segment (A) (green double arrow) to the intended device implantation site (B)
(white double arrow). Any visible side branches originating from this region of interest were analyzed. The conventional QCA analysis automatically delineates an
obstruction segment in the main branch (B) (yellow double arrow). An example of side branch analysis is shown in C and D. DS ¼ diameter stenosis; QCA ¼ quantitative
coronary angiography; RVD ¼ reference vessel diameter; SBO ¼ side branch occlusion.
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1056coronary intervention procedure and at 6, 12, and
18 h after the procedure or at hospital discharge,
whichever came ﬁrst. These blood samples were sent
to the central core laboratory (ICON Laboratories,
Dublin, Ireland) and to local hospital laboratories
for analysis. Whenever clinically indicated, addi-
tional sampling could be taken and analyzed by the
local hospital laboratories.
This yielded a mixture of local and central lab-
oratories’ biomarker results with different upper
limits of normal (ULN). When both local and central
laboratories’ cardiac enzyme data were available
at the same time, the clinical events committee
used the central laboratories’ results for the adju-
dication of MI.DEFINITIONS OF PERIPROCEDURAL MYOCARDIAL
INFARCTION. In this study protocol, MI was deﬁned
according to the following deﬁnitions (14–16): 1) per-
protocol (modiﬁed World Health Organization) deﬁ-
nition; and 2) extended historical deﬁnition (14). In
the protocol, MI without distinction of being sponta-
neous or PMI is deﬁned by elevation of total creatine
kinase (CK) to >2 ULN along with elevated or
“positive” creatine kinase-myocardial band (CK-MB).
A hierarchical approach was used for the adjudication
of PMI based on CB availability when an analyzable
CB was missing (extended historical deﬁnition:
CK-MB mass when CK was not available, cardiac
troponin when CK and CK-MB mass were not avail-
able). All protocol deﬁned clinical outcomes were
TABLE 1 Baseline Demographic Data and Angiographic Characteristics in Patients
Absorb
(335 Patients,
364 Lesions)
EES
(166 Patients,
182 Lesions) p Value
Age, yrs 61.5  10.0 60.9  10.0 0.51
Male 253 (75.5) 132 (79.5) 0.32
Body mass index, kg/m2 27.9  4.1 28.1  3.7 0.56
Current smoker 79 (23.6) 36 (21.7) 0.64
Hypertension requiring treatment 220 (65.7) 112 (67.5) 0.69
Dyslipidemia requiring treatment 238 (71.0) 123 (74.1) 0.47
Any diabetes mellitus 80 (23.9) 40 (24.1) 0.96
Unstable angina 68 (20.3) 37 (22.3) 0.61
Family history of coronary artery disease 112 (36.6) 64 (41.3) 0.33
Previous history of myocardial infarction 93 (28.0) 48 (28.9) 0.83
Number of lesions/patient 1.1  0.3 1.1  0.3 0.81
Lesion location
Right coronary artery 95 (26.1) 56 (30.8) 0.25
Left anterior descending artery 163 (44.8) 84 (46.2) 0.76
Left circumﬂex artery or ramus 106 (29.1) 42 (23.1) 0.13
ACC/AHA lesion complexity
A 5 (1.4) 1 (0.6) 0.67
B1 193 (53.2) 90 (50.0) 0.49
B2 159 (43.8) 87 (48.3) 0.32
C 6 (1.7) 2 (1.1) 1.00
TIMI ﬂow grade 0 or 1 1 (0.3) 2 (1.1) 0.26
Calciﬁcation, moderate or severe 46 (12.7) 28 (15.5) 0.37
Tortuosity, moderate or severe 34 (9.4) 13 (7.2) 0.39
Eccentric 357 (98.3) 178 (99.4) 0.43
Thrombus 5 (1.4) 4 (2.2) 0.49
Bifurcation 13 (3.6) 5 (2.8) 0.62
Reference vessel diameter, mm 2.59  0.38 2.63  0.40 0.36
Percentage of diameter stenosis 58.6  11.1 59.7  11.6 0.30
Obstruction lesion length, mm 13.8  6.5 13.8  6.6 1.00
Values are mean  SD or n (%).
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; EES ¼ everolimus-eluting stent(s).
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1057adjudicated by an independent Clinical Events Com-
mittee. Fourteen patients presented with recent MI at
entry with normalized CK-MB according to the pro-
tocol, but with/without troponin elevation. These
patients were excluded for post-CB analysis. Post-hoc
adjudication was performed according to Society of
Cardiovascular Angiography and Interventions deﬁ-
nition and the universal third deﬁnition. The details
are described in the Online Appendix.
STATISTICAL ANALYSIS. All analyses were per-
formed on the intention-to-treat basis, using all pa-
tients randomized in the study, regardless of the
treatment actually received. The counts of PMI are
summarized and tabulated according to the fre-
quency. Categorical variables were compared by
Fisher exact test. Continuous variables are presented
as mean  SD and were compared by nonparametric
test. The logistic regression model was performed
for Table 5. Detail of statistical analysis is provided
in the Online Appendix. In addition to the device
type, signiﬁcant variables (p < 0.10) in the univariate
analysis were forced into a multivariate logistic
regression model to predict PMI. All statistical tests
were performed with SPSS (version 22.0 for Windows,
SPSS, Chicago, Illinois). A 2-sided p value of <0.05
was considered to indicate statistical signiﬁcance.
RESULTS
PATIENT AND PROCEDURAL CHARACTERISTICS.
Patient demographics were comparable in both arms
(Table 1). The lesion characteristics such as type B2/C
lesions, bifurcation lesions, eccentricity, moderate/
severe tortuosity, thrombus, and moderate/severe
calciﬁcation were similar between the 2-treatment
arms.
AVAILABILITY OF CARDIAC BIOMARKERS OF
MYOCARDIAL INJURY. Within 24 h before the index
procedure, 920 blood time points for the assessment
of CB were available with 458 central and 462 local
biomarker data. At least 1 of the 3 CB was available in
486 patients (97.0%) within 6 h and in 495 patients
(98.8%) within 24 h before the index procedure. At
least 1 of the 3 CB was available in 490 patients
(97.8%) within 48 h after the index procedure. In the
serial sample analysis, 1,446 blood time points for the
assessment of CB were available with 572 central and
874 local biomarker data (Figure 3). A total of 3,813
blood samples with 1,257 CK, 1,253 CK-MB, and 1,303
troponin values were available. For the post-
procedural peak-level assessment of each CB, the
central biomarker data was used in 58.4% for CK
(271 of 464), 70.9% for CK-MB (337 of 475), and 45.0%for troponin (213 of 473). The availability of paired
biomarkers (CK and CK-MB) for per-protocol PMI
adjudication at post-procedure was available in
93.4% (313 of 335) of the Absorb arm and 96.4%
(160 of 166) of the EES arm. Troponin was available
in 98.8% (325 of 335) of the Absorb arm and 97.6%
(160 of 166) of the EES arm.
QUALITATIVE AND QUANTITATIVE ANGIOGRAPHIC
ASSESSMENT. The frequencies of “angiographic
complications” are shown in Table 2. In the present
analysis, 335 patients with 988 side branches in the
Absorb arm and 166 patients with 503 side branches in
the EES arm were assessed. Incidence of any “angio-
graphic complications” and SBO was similar between
the 2 treatment arms (any complications: Absorb:
16.4% vs. EES: 19.9%, p ¼ 0.39; SBO: 5.3% vs. 7.6%,
p ¼ 0.07). The incidence of post-procedural SBO in
the obstruction segment was signiﬁcantly lower in
the Absorb arm than in the EES arm (4.3% vs. 6.8%,
FIGURE 3 Time Points and Availability for the Assessment of CB Pre- and
Post-Procedure
A total of 920 blood time points for the assessment of cardiac biomarkers (CB) were
available with 458 central and 462 local biomarker data within 24 h before the index
procedure. At least 1 of the 3 CB was available in 486 patients (97.0%) within 6 h and 495
patients (98.8%) within 24 h before the index procedure. At least 1 of the 3 CB was
available in 490 patients (97.8%) within 48 h after the index procedure. In the serial
sample analysis, 1,446 blood time points for the assessment of CB were available with 572
central and 874 local biomarker data.
Ishibashi et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 8 , 2 0 1 5
Periprocedural Cardiac Biomarker Rise in ABSORB II J U L Y 2 0 1 5 : 1 0 5 3 – 6 3
1058p ¼ 0.046), although there were no signiﬁcant dif-
ferences in the incidence of SBO according to the
reference vessel diameter (RVD) size (RVD # 0.5 mm,
0.5 mm < RVD # 1.0 mm, 1.0 mm < RVD). Each type
(type 1, type 2, and type 3) of “anatomic complica-
tions” after revascularization was similar between
the 2 treatment arms. However, 2 abrupt occlusions
were documented after EES implantation (Table 2).
INCIDENCE OF CARDIAC BIOMARKER RISE AND
PERIPROCEDURAL MI. As recently described (17),
we compared the peak value of the 3 CB valuespost-procedure according to 5 rise categories (CB:
>2 ULN, >5 ULN, >10 ULN, > 35 ULN, and >70
ULN) after scaffold or stent implantation. In the
present study, the rise of 3 CB subcategorized in
7 different ranges was comparable between the 2
treatment arms (Table 3).
Per-protocol PMI (World Health Organization deﬁ-
nition) occurred in 13 of 335 patients (3.9%) in the
Absorb arm and 2 of 166 patients (1.2%) in the EES arm
(p ¼ 0.16). Incidence of PMI per protocol according to
“anatomic complications” assessed by angiography
was similar between the 2 treatment arms (Table 4).
In the post-hoc adjudication, the PMI rates according
to the third universal deﬁnition and the Society of
Cardiovascular Angiography and Interventions deﬁ-
nition were 14.2% versus 10.6% (p ¼ 0.31) and 0.6%
versus 0.6% (p ¼ 1.00), respectively.
CARDIAC BIOMARKER RISE, ANGIOGRAPHY, AND
GRAYSCALE/RADIOFREQUENCY IVUS. Figure 4
shows the magnitude of post-procedural CB rise
in patients with “anatomic complications” (type 1 and
type2)assessedbyangiography.CBrise subcategorized
in 5 different ranges was similar between the 2 treat-
ment arms in the patients with “anatomic complica-
tions.” Incidence of CB rise assessed by IVUS (data not
shown) was similar between the 2 treatment arms
as well as “angiographic complications.” There was
no statistical signiﬁcance between IVUS ﬁnding and
post-procedure CB rising (Online Appendix).
PREDICTORS OF PERIPROCEDURAL MYOCARDIAL
INFARCTION. In the multivariable analyses, treat-
ment with overlapping devices was the only inde-
pendent determinant of per-protocol PMI (odds ratio
[OR]: 5.07, 95% conﬁdence interval [CI]: 1.78 to 14.41,
p ¼ 0.002) (Table 5).DISCUSSION
The present study is the ﬁrst randomized clinical trial
to analyze the difference in frequencies of PMI and CB
rise after implantation of Absorb scaffold or EES.
The main ﬁndings of this study follow: 1) Incidence of
any anatomic complications including SBO assessed
by angiography was similar between the 2 treatment
arms (Absorb: 16.4% vs. EES: 19.9%, p ¼ 0.39). 2) Per-
protocol PMI (World Health Organization deﬁnition)
occurred in 13 of 335 patients (3.9%) in the Absorb arm
and 2 of 166 patients (1.2%) in the EES arm (p ¼ 0.16).
Of 15 patients with per-protocol PMI, 10 PMI
(66.7%) were caused by SBO, whereas 3 (20.0%) were
due to other anatomical complications. 3) Treatment
with overlapping devices was an independent
TABLE 2 Anatomic Complications Assessed by Angiography
Per-Patient Analysis
Absorb
(n ¼ 335)
EES
(n ¼ 166) p Value
Any anatomic complications assessed
by angiography
16.4 (56) 19.9 (33) 0.39
Type 1 anatomic complication assessed
by angiography
SBO 12.5 (43) 15.7 (26) 0.41
SBO after pre-dilation 0 (0) 0 (0) 1.00
SBO after device implantation 12.5 (43) 15.7 (26) 0.41
SBO improvement after NTG 0.9 (3) 0 (0) 0.55
SBO after procedure 11.6 (40) 15.7 (26) 0.26
Type 2 anatomic complication assessed by
angiography
Abrupt closure 0 (0) 1.8 (2) 0.11
Distal embolization 0.3 (1) 0 (0) 1.00
Coronary perforation 0.6 (2) 0 (0) 1.00
Flow-limiting dissection (NHLBI type F) 0.3 (1) 0 (0) 1.00
Coronary dissection after pre-dilation
(NHLBI type D or E)
1.8 (6) 1.2 (2) 1.00
Coronary dissection after device implantation 0.3 (1) 0.6 (1) 1.00
Thrombus during procedure 0.3 (1) 0 (0) 1.00
Disruption of collateral ﬂow 0.3 (1) 1.2 (2) 0.26
Per-Side Branch Analysis (n ¼ 998) (n ¼ 503)
Incidence of SBO after procedure 5.3 (52) 7.6 (39) 0.07
Location of occluded side branch
Outside scaffold segment 0 (0) 0 (0) 1.00
To-be-scaffold segment outside obstruction 0.9 (9) 1.0 (5) 1.00
Obstruction segment 4.3 (42) 6.8 (34) 0.046
RVD of occluded side branch
RVD > 1.0 mm 0.9 (9) 1.2 (6) 0.59
0.5 mm < RVD # 1.0 mm 2.9 (29) 4.2 (21) 0.22
RVD # 0.5 mm 1.3 (13) 2.4 (12) 0.14
Values are % (n).
EES ¼ everolimus-eluting stent(s); NHLBI ¼ National Heart, Lung, and Blood Institute; NTG ¼ nitroglycerin;
RVD ¼ reference vessel diameter; SBO ¼ side branch occlusion.
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1059determinant of per-protocol PMI (OR: 5.07, 95% CI:
1.78 to 14.41, p ¼ 0.002). 4) The CB rise sub-
categorized in 7 different ranges was comparable be-
tween the 2 treatment arms.
AVAILABILITY OF CARDIAC BIOMARKER AND PERI-
PROCEDURAL CARDIAC BIOMARKER RISE. This is the
ﬁrst scaffold or metallic stent study in which 3
different CB values were available at a central core
laboratory, the compliance of enzyme collection was
high (CK: 95.3%, CK-MB: 97.5%, troponin: 97.1%). Of
note, in the RESOLUTE-All Comers (A Randomized
Comparison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous Coronary
Intervention) trial (14), an analyzable dataset for
cardiac troponin was available in 55.3% (1,173 of 2,121)
of patients. In addition, 44.1% (935 of 2,121) of pa-
tients had an analyzable dataset for both cardiac
troponin and CK-MB (14). In 10 patients, 3 CB simul-
taneously increased, whereas in 127 patients, discor-
dance in CB rise was documented, suggesting that
the sensitivity of CB to detect myocardial damage
varies according to the criteria and type of CB (Online
Figure 2).
The prognostic relevance of CB rise is shown by
Park et al. (18), in a large cohort of 23,604 patients,
the prognostic implication of a CK-MB rise 3 to 5
ULN. Myint et al. (19) reported that prognostic sig-
niﬁcance of troponin in acute coronary syndrome
attenuates with increased age and that older age is
associated with a worse prognosis compared with the
prognosis of younger counterparts given the same
level of troponin rise, even at very low levels of
troponin.
ANATOMICCOMPLICATIONSASSESSEDBYANGIOGRAPHY/
IVUSAND PERIPROCEDURAL CARDIAC BIOMARKER RISE
WITH ABSORB OR EES. In the previous publication
using the data of the Absorb Extend registries with a
matched cohort from SPIRIT (Clinical Evaluation of
the Xience V Everolimus Eluting Coronary Stent
System) trials (9), it was reported that the Absorb
scaffold was associated with a higher SBO rate than
Xience was. The difference was more pronounced
with small side branches with an RVD #0.5 mm.
However, there was no signiﬁcant difference in the
incidence of post-procedure CK-MB elevation. It was
hypothesized that the difference in SBO was due to
the difference in the design of the 2 devices. The
Absorb scaffold has thicker (156 mm) and wider struts
(up to 800 mm) with a higher surface coverage ratio
(26% to 32%) than Xience does (thickness: 90 mm,
widths: up to 428 mm, surface coverage: 13%).
Therefore small side branches could be more fre-
quently occluded by the implantation of Absorbscaffold. At variance with the report by Muramatsu
et al. (9), the Absorb, compared with EES, showed a
trend toward lower incidence of post-procedural SBO.
Of note, most of the SBO occurred in small side
branches of RVD <1.0 mm in both of treatment arms
(Table 2). Although the nominal sizes of devices used
(3.01  0.31 mm vs. 3.05  0.28 mm, p ¼ 0.10) and
frequency of post-device dilation were comparable
(60.7% vs. 58.8%, p ¼ 0.67), the nominal balloon size
and the pressure used during either implantation or
post-dilation was larger and higher in the EES arm, so
that the expected balloon diameter tended to be larger
accordingly (3.29  0.35 mm vs. 3.35  0.37 mm,
p¼0.15) (17), the acute gain inminimal lumendiameter
(quantitative coronary angiography measurement
by the core laboratory) was signiﬁcantly larger in
the EES arm (1.15  0.38 mm vs. 1.46  0.38 mm,
p < 0.001) (17). Whether the aggressive (post)-
dilation may have resulted in a higher incidence
TABLE 4
Assessed
Per-proto
Type 1: SB
SBO aft
SBO aft
SBO imp
SBO aft
Type 2: an
Abrupt
Distal e
Coronar
Flow-lim
Coronar
NHL
Coronar
impl
Thromb
Disrupti
Nonindent
Per-protoco
“positive” C
PMI ¼ pe
TABLE 3 Comparison of the Peak Value of Cardiac Enzyme Rise Post-Procedure Using Central Lab and/or Local Lab Results
CK
n ¼ 464 of 487 (95.3%)
CK-MB*
n ¼ 475 of 487 (97.5%)
cTn
n ¼ 473 of 487 (97.1%)
Absorb
(n ¼ 306)
Xience
(n ¼ 158) p Value
Absorb
(n ¼ 315)
Xience
(n ¼ 160) p Value
Absorb
(n ¼ 316)
Xience
(n ¼ 157) p Value
Mean  SD 0.71  0.63 0.65  0.64 0.380 1.33  2.12 1.09  1.65 0.180 12.09  30.24 8.28  20.20 0.138
>2 ULN 5.2 (16) 1.9 (3) 0.135 13.7 (43) 10.0 (16) 0.304 48.1 (152) 45.9 (72) 0.696
>5 ULN 0 (0) 0.6 (1) 0.341 5.1 (16) 2.5 (4) 0.232 29.7 (94) 25.5 (40) 0.386
>10 ULN 0 (0) 0 (0) 1.000 0.6 (2) 0.6 (1) 1.000 19.0 (60) 15.3 (24) 0.372
>35 ULN 0 (0) 0 (0) 1.000 0 (0) 0 (0) 1.000 6.0 (19) 3.8 (6) 0.387
>70 ULN 0 (0) 0 (0) 1.000 0 (0) 0 (0) 1.000 3.5 (11) 1.3 (2) 0.236
Values are % (n) unless otherwise indicated. *Fourteen patients presented with recent myocardial infarction at entry with normalized CKMB according to the protocol were
excluded for post CB analysis.
CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band; cTn ¼ cardiac troponin; EES ¼ everolimus-eluting stent(s); ULN ¼ upper limit of normal.
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1060of post-procedural SBO in the EES arm—due to
the presence of the bifurcation carina shift and/or
plaque shift into the oriﬁce of side branch
(16,20)—remains speculative. Among the patients
with post-dilation, the peak ratio of CK-MB post-
procedure was signiﬁcantly higher in the Absorb
arm than in the EES arm (1.43  2.41 vs. 1.00 
1.89, p ¼ 0.02). The current protocol did not
recommend post-dilation of the Absorb device with
a balloon larger than 0.25 mm with respect to the
nominal size of the device. The post-procedural CB
rise with the patients who underwent post-dilation
seems to justify retrospectively this conservative
recommendation.Incidence of Per-Protocol PMI According to Anatomic Complications
by Angiography
Absorb (n ¼ 335) EES (n ¼ 166) p Value
col PMI 3.9 (13) 1.2 (2) 0.16
O 2.7 (9) 0.6 (1) 0.18
er pre-dilation 0 (0) 0 (0) 1.00
er device implantation 2.7 (9) 0.6 (1) 0.18
rovement after NTG 0 (0) 0 (0) 1.00
er procedure 2.7 (9) 0.6 (1) 0.18
giographic other complication 0.6 (2) 0.6 (1) 1.00
closure 0 (0) 0.6 (1) 1.00
mbolization 0.3 (1) 0 (0) 1.00
y perforation 0 (0) 0 (0) 1.00
iting dissection, NHLBI type F 0 (0) 0 (0) 1.00
y dissection after pre-dilation,
BI type D or E
0.3 (1) 0 (0) 1.00
y dissection after device
antation
0 (0) 0 (0) 1.00
us during procedure 0 (0) 0 (0) 1.00
on of collateral ﬂow 0 (0) 0 (0) 1.00
iﬁable mechanism causes 0.6 (2) 0 (0) 1.00
l PMI is deﬁned as the elevation of total CK to >2 ULN along with elevated or
K-MB without clinical symptom and electrocardiogram change.
riprocedural myocardial infarction; other abbreviations as in Tables 1 to 3.As previously reported, atherosclerotic plaque
burden pre-intervention is correlated with an in-
creased rate of PMI as evidenced by subsequent
CB rise (21). Atherosclerotic plaque with larger
necrotic core are at higher risk of plaque rupture and
microembolization during percutaneous coronary
intervention with subsequent CB rise (22,23). The
present study also documented that dyslipidemia
requiring treatment was protective for troponin rise
>5 ULN, whereas the incidence of CB rise assessed
by IVUS was similar between the 2 treatment arms.
It has been hypothesized that statins may exert
anti-inﬂammatory effects, resulting in reduction
of microembolization by stabilizing the underlying
plaque (24).
ANATOMIC COMPLICATIONS ASSESSED BY ANGIO-
GRAPHY AND PERIPROCEDURAL MI WITH ABSORB
OR EES. Previous studies revealed that SBO was the
most common cause of PMI (20,25). In the present
study, 15 patients with per-protocol PMI, 10 (66.7%)
were angiographically classiﬁed as type 1 (SBO)
whereas 3 (20.0%) were type 2 (other anatomic
complication). In 2 patients (13.3%), no angiographic
complications could be identiﬁed. Thus, our results
are in concordance with previous studies (16,26,27).
PREDICTORS FOR PERIPROCEDURAL RISE OF CARDIAC
BIOMARKER FOR INJURY. The predictors of PMI can be
broadly categorized as patient-, lesion-, and
procedure-related risk factors (16,20). In the SPIRIT IV
trial, which randomized 3,687 patients in a 2:1 fashion
to receive either EES or PES, the total stent length was
a strong predictor of PMI by criteria using CK or
troponin (16). In the present study, by multivariable
analysis, treatment with overlapping devices was the
independent determinant of per-protocol PMI (OR:
5.07, 95% CI: 1.78 to 14.41, p ¼ 0.002), whereas there
was overall no signiﬁcant difference in PMI between
the 2 device types (Absorb vs. EES). In the Absorb
FIGURE 4 Anatomic Complication Assessed by Angiography and Periprocedural CB Rise
The ﬁgure shows magnitude of post-procedural CB rise—(A) CK, (B) CK-MB, (C) cTn—for the patients with side branch occlusion after percutaneous coronary intervention
(blue bars) and those with the other anatomical complications (red bars). *Fourteen patients presented with recent myocardial infarction at entry with normalized
CK-MB according to the protocol were excluded for post-CB analysis. CB ¼ cardiac biomarkers; CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band;
cTn ¼ cardiac troponin.
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1061arm, the treatment with overlapping was associated
with risk of PMI with a 3.59 OR (p ¼ 0.03), whereas in
the EES arm, OR was 5.07 (p ¼ 0.28) in the EES arm.
The p value for interaction was not signiﬁcantly
different (p ¼ 0.65), suggesting that overlapping is
associated with higher risk of MI in both the Absorb
and Xience arms. One MI (non–Q-wave) was attrib-
uted to deﬁnite scaffold thrombosis involving over-
lapping scaffolds. Of note, in a juvenile porcine model
(28), overlapping Absorb scaffolds, compared with
nonoverlapping scaffolds, showed delayed healing on
histology and optical coherence tomography and
slower tissue coverage: the coverage of the over-
lapping segment was 80.1% and 99.5% at 28 and 90
days after implantation respectively, suggesting thatcomplete coverage in humans may take up to
18 months. Similar ﬁndings (29,30)—delayed healing
and promotion of inﬂammation at sites of overlap—
have been reported in the atherosclerotic rabbit model
implanted with EES, suggesting the general detri-
mental effect and potential biohazard of overlapping
devices. Adjacent implantation of scaffolds instead of
true overlapping may circumvent this problem.
STUDY LIMITATIONS. The results of the current
substudy are a post-hoc analysis. The study was not
powered to detect difference in clinical events such
as PMI and per-protocol deﬁnition of PMI does not
include clinical symptoms or electrocardiographic
changes. Given the mixture and wide range of
troponin assays used across participating hospitals,
TABLE 5 Predictors of Per-Protocol PMI
Univariate Logistic
Regression
Multivariate Model (I, II,
III, IV,V and Device Type)
OR (95% CI) p Value OR (95% CI) p Value
Patient-related factors
Age, yrs 1.02 (0.96–1.07) 0.56 — —
Male 1.21 (0.34–4.37) 0.77 — —
Body mass index, kg/m2 0.94 (0.81–1.08) 0.36 — —
Current smoker 1.71 (0.57–5.11) 0.34 — —
Hypertension requiring treatment 0.43 (0.15–1.22) 0.11 — —
Dyslipidemia requiring treatment 0.57 (0.20–1.64) 0.30 — —
Any diabetes mellitus 0.48 (0.11–2.16) 0.34 — —
Unstable angina 0.94 (0.26–3.40) 0.93 — —
Lesion-related factors assessed
by angiography
Pre-procedural diameter stenosis, % 0.98 (0.93–1.02) 0.28 — —
Pre-procedural minimal lumen
diameter, mm
1.38 (0.28–6.72) 0.69 — —
Pre-procedural reference diameter, mm 0.48 (0.12–1.92) 0.30 — —
Obstruction length, mm 0.99 (0.92–1.08) 0.85 — —
Pre-procedural curvature, cm-1 0.20 (0.19–2.16) 0.19 — —
Lesion-related factors assessed
by grayscale IVUS
Pre-procedural minimal lumen
area, mm2
0.78 (0.35–1.70) 0.53 — —
Pre-procedural EEM, mm2 0.99 (0.86–1.16) 0.98 — —
Pre-procedural mean total plaque
area in treated region, mm2
1.05 (0.88–1.27) 0.58 — —
Pre-procedural total plaque volume
in treated region, mm3
1.00 (1.00–1.01) 0.22 — —
Pre-procedural plaque burden in treated
region, %
1.03 (0.99–1.07) 0.14 — —
Lesion-related factors assessed by
IVUS-VH
Pre-procedural dense calcium, mm2 1.86 (0.15–23.83) 0.63 — —
Pre-procedural necrotic core, mm2 1.16 (0.34–3.99) 0.81 — —
Pre-procedural ﬁbrotic tissue, mm2 1.33 (0.70–2.51) 0.39 — —
Pre-procedural ﬁbro-fatty tissue, mm2 0.92 (0.63–1.34) 0.67 — —
Treatment-related factors
Treatment with overlapping devices 5.32 (1.88–15.05) <0.01 5.07 (1.78–14.41) 0.002
Device type, Absorb vs. EES 0.30 (0.07–1.35) 0.12 3.03 (0.67–13.74) 0.150
Post-dilation 1.18 (0.40–3.50) 0.77 — —
Bail-out 3.79 (0.45–31.96) 0.22 — —
Expected balloon diameter of the
last balloon, mm
3.06 (0.76–12.33) 0.12 — —
Dashes indicate that there were no applicable data.
CI ¼ conﬁdence interval; IVUS ¼ intravascular ultrasound; OR ¼ odds ratio; VH ¼ virtual histology; other
abbreviations as in Tables 1 and 4.
PERSPECTIVES
WHAT IS KNOWN? A potential concern exists that
a bioresorbable vascular scaffold, compared with
newer-generations of DES, might be associated with a
higher incidence of periprocedural myocardial injury
and PMI.
WHAT IS NEW? Our results conﬁrmed that there
were no differences in the incidence of CB rise and
PMI between Absorb and EES.
WHAT IS NEXT? Device overlap might be a precip-
itating factor of myocardial injury.
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1062the proportion of elevated troponin and periproce-
dural rise could be depended on the proportion of
contemporary or sensitive assays compared withconventional troponin assays. The difference in the
health care system could inﬂuence the long-term
clinical outcomes, however, such variances are less
relevant to the current analysis focusing on the acute
procedural outcomes.
CONCLUSIONS
There were no statistically signiﬁcant differences in
the incidence of CB rise and PMI between Absorb and
EES. Overlapping of scaffolds or stents might be a
precipitating factor of myocardial injury. Larger ran-
domized trials are currently ongoing to conﬁrm these
ﬁndings. As demonstrated in the present study,
which collected all 3 CB, binary deﬁnition of PMI is
not only dependent on the selection of CB but also on
the thresholds of the CB rise which are arbitrarily
chosen.
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